Cowen Maintains Buy on MBX Biosciences, Inc. Common Stock (MBX) Mar 2026
The MBX analyst rating held steady on March 12, 2026 when Cowen & Co. maintained a Buy on MBX Biosciences, Inc. Common Stock (MBX). Cowen said it is “confident” the company’s canvu Phase III program will succeed. This maintained rating arrives alongside a short-term stock move of 3.65% ($0.98) and follows ongoing clinical milestones for the company.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
